Vascular complications of cystathionine β-synthase deficiency: Future directions for homocysteine-to-hydrogen sulfide research

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 1, 2011, Pages

  Beard Jr , Richard S ^a   Bearden, Shawn E ^a  

^a Nucl Eng Idaho State University   (United States)

Author keywords

Arteriosclerosis; Disease risk factors; Thrombosis; Transsulfuration

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; HYDROGEN SULFIDE; MICRORNA; MUSCIMOL; SIMVASTATIN;

ANGIOGENESIS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CYSTATHIONINE BETA SYNTHASE DEFICIENCY; DIET THERAPY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME METABOLISM; EPIGENETICS; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS;

EID: 78651339218     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00598.2010     Document Type: Review

References (187)

1. Abbott MH, Folstein SE, Abbey H, Pyeritz RE. Psychiatric manifestations of homocystinuria due to cystathionine β-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness. Am J Med Genet 26: 959-969, 1987.
2. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16: 1066-1071, 1996.
3. Agnati LF, Genedani S, Rasio G, Galantucci M, Saltini S, Filaferro M, Franco R, Mora F, Ferre S, Fuxe K. Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration. J Neural Transm 112: 163-169, 2005.
4. Akahoshi N, Kobayashi C, Ishizaki Y, Izumi T, Himi T, Suematsu M, Ishii I. Genetic background conversion ameliorates semi-lethality and permits behavioral analyses in cystathionine β-synthase-deficient mice, an animal model for hyperhomocysteinemia. Hum Mol Genet 17: 1994-2005, 2008.
5. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299: 2027-2036, 2008.
6. Almgren B, Eriksson I, Hemmingsson A, Hillerdal G, Larsson E, Aberg H. Abdominal aortic aneurysm in homocystinuria. Acta Chir Scand 144: 545-548, 1978.
7. Babiloni C, Bosco P, Ghidoni R, Del Percio C, Squitti R, Binetti G, Benussi L, Ferri R, Frisoni G, Lanuzza B, Cassetta E, Anello G, Gurzi M, Bartesaghi S, Lizio R, Tombini M, Rossini PM. Homocysteine and electroencephalographic rhythms in Alzheimer disease: a multicentric study. Neuroscience 145: 942-954, 2007.
8. Bagi Z, Ungvari Z, Koller A. Xanthine oxidase-derived reactive oxygen species convert flow-induced arteriolar dilation to constriction in hyperhomocysteinemia: possible role of peroxynitrite. Arterioscler Thromb Vasc Biol 22: 28-33, 2002.
9. Banerjee R, Evande R, Kabil O, Ojha S, Taoka S. Reaction mechanism and regulation of cystathionine beta-synthase. Biochim Biophys Acta 1647: 30-35, 2003.
10. Bass HN, LaGrave D, Mardach R, Cederbaum SD, Fuster CD, Chetty M. Spontaneous pneumothorax in association with pyridoxine-responsive homocystinuria. J Inherit Metab Dis 20: 831-832, 1997.
11. Baumbach GL, Sigmund CD, Bottiglieri T, Lentz SR. Structure of cerebral arterioles in cystathionine β-synthase-deficient mice. Circ Res 91: 931-937, 2002.
12. Bearden SE, Beard RS Jr, Pfau JC. Extracellular transsulfuration generates hydrogen sulfide from homocysteine and protects endothelium from redox stress. Am J Physiol Heart Circ Physiol 299: H1568-H1576, 2010.
13. 2S induces a suspended animation-like state in mice. Science 308: 518, 2005.
14. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578-1588, 2006.
15. Bosch-Marce M, Pola R, Wecker AB, Silver M, Weber A, Luedemann C, Curry C, Murayama T, Kearney M, Yoon YS, Malinow MR, Asahara T, Isner JM, Losordo DW. Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia. Vasc Med 10: 15-22, 2005.
16. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68: 1809-1814, 2007.
17. Budy B, O'Neill R, DiBello PM, Sengupta S, Jacobsen DW. Homocysteine transport by human aortic endothelial cells: identification and properties of import systems. Arch Biochem Biophys 446: 119-130, 2006.
18. Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, Zhu YC. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc Res 76: 29-40, 2007.
19. Carnicer R, Guzman MA, Acin S, Surra JC, Navarro MA, Arbones-Mainar JM, Arnal C, Morales R, Osada J. Genetic background in apolipoprotein A-I and cystathionine β-synthase deficiency. Front Biosci 13: 5155-5162, 2008.
20. Carnicer R, Navarro MA, Arbones-Mainar JM, Arnal C, Surra JC, Acin S, Sarria A, Blanco-Vaca F, Maeda N, Osada J. Genetically based hypertension generated through interaction of mild hypoalphalipoproteinemia and mild hyperhomocysteinemia. J Hypertens 25: 1597-1607, 2007.
21. Carnicer R, Navarro MA, Guillen N, Arbones-Mainar JM, Surra JC, Acin S, Osada J. Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine β-synthase and apolipoprotein A-I. Naunyn Schmiedebergs Arch Pharmacol 377: 35-43, 2008.
22. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, Chen MF, Pai A, John SW, Smith RS, Bottiglieri T, Bagley P, Selhub J, Rudnicki MA, James SJ, Rozen R. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 10: 433-443, 2001.
23. Cheung NS, Peng ZF, Chen MJ, Moore PK, Whiteman M. Hydrogen sulfide induced neuronal death occurs via glutamate receptor and is associated with calpain activation and lysosomal rupture in mouse primary cortical neurons. Neuropharmacology 53: 505-514, 2007.
24. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149-1155, 1991.
25. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55: 1449-1455, 1998.
26. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 91: 6-14, 1996.
27. Collins JE, Brenton DP. Pancreatitis and homocystinuria. J Inherit Metab Dis 13: 232-233, 1990.
28. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138: 707-717, 1997.
29. Dayal S, Devlin AM, McCaw RB, Liu ML, Arning E, Bottiglieri T, Shane B, Faraci FM, Lentz SR. Cerebral vascular dysfunction in methionine synthase-deficient mice. Circulation 112: 737-744, 2005.
30. Dayal S, Lentz SR. Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol 28: 1596-1605, 2008.
31. Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, Lentz SR. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood 108: 2237-2243, 2006.
32. de Groot PG, Willems C, Boers GH, Gonsalves MD, van Aken WG, van Mourik JA. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 13: 405-410, 1983.
33. de Koning L, Hu FB. Homocysteine lowering in end-stage renal disease: is there any cardiovascular benefit? Circulation 121: 1379-1381, 2010.
34. Devlin AM, Bottiglieri T, Domann FE, Lentz SR. Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. J Biol Chem 280: 25506-25511, 2005.
35. Donahue JE, Johanson CE. Apolipoprotein E, amyloid-β, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol 67: 261-270, 2008.
36. Du J, Hui Y, Cheung Y, Bin G, Jiang H, Chen X, Tang C. The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels 19: 75-80, 2004.
37. Duan J, Murohara T, Ikeda H, Sasaki K, Shintani S, Akita T, Shimada T, Imaizumi T. Hyperhomocysteinemia impairs angiogenesis in response to hindlimb ischemia. Arterioscler Thromb Vasc Biol 20: 2579-2585, 2000.
38. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygard O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 300: 795-804, 2008.
39. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 106: 483-491, 2000.
40. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 31: 1069-1075, 2000.
41. El-Sammak M, Kandil M, El-Hifni S, Hosni R, Ragab M. Elevated plasma homocysteine is positively associated with age independent of C677T mutation of the methylenetetrahydrofolate reductase gene in selected Egyptian subjects. Int J Med Sci 1: 181-192, 2004.
42. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H, Chow CW, Lefer DJ. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA 104: 15560-15565, 2007.
43. Eto K, Asada T, Arima K, Makifuchi T, Kimura H. Brain hydrogen sulfide is severely decreased in Alzheimer's disease. Biochem Biophys Res Commun 293: 1485-1488, 2002.
44. Eto K, Ogasawara M, Umemura K, Nagai Y, Kimura H. Hydrogen sulfide is produced in response to neuronal excitation. J Neurosci 22: 3386-3391, 2002.
45. Evande R, Blom H, Boers GH, Banerjee R. Alleviation of intrasteric inhibition by the pathogenic activation domain mutation, D444N, in human cystathionine β-synthase. Biochemistry 41: 11832-11837, 2002.
46. Folin M, Baiguera S, Gallucci M, Conconi MT, Di Liddo R, Zanardo A, Parnigotto PP. A cross-sectional study of homocysteine-, NO-levels, and CT-findings in Alzheimer dementia, vascular dementia and controls. Biogerontology 6: 255-260, 2005.
47. Gallagher PM, Ward P, Tan S, Naughten E, Kraus JP, Sellar GC, McConnell DJ, Graham I, Whitehead AS. High frequency (71%) of cystathionine beta-synthase mutation G307S in Irish homocystinuria patients. Hum Mutat 6: 177-180, 1995.
48. Gallucci M, Zanardo A, De Valentin L, Vianello A. Homocysteine in Alzheimer disease and vascular dementia. Arch Gerontol Geriatr Suppl: 195-200, 2004.
49. Griffiths R, Tudball N. The molecular defect in a case of (cystathionine β-synthase)-deficient homocystinuria. Eur J Biochem 74: 269-273, 1977.
50. Guillen N, Navarro MA, Arnal C, Noone E, Arbones-Mainar JM, Acin S, Surra JC, Muniesa P, Roche HM, Osada J. Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. Physiol Genomics 37: 187-198, 2009.
51. Guzman MA, Navarro MA, Carnicer R, Sarria AJ, Acin S, Arnal C, Muniesa P, Surra JC, Arbones-Mainar JM, Maeda N, Osada J. Cystathionine β-synthase is essential for female reproductive function. Hum Mol Genet 15: 3168-3176, 2006.
52. Hamelet J, Demuth K, Paul JL, Delabar JM, Janel N. Hyperhomocysteinemia due to cystathionine β-synthase deficiency induces dysregulation of genes involved in hepatic lipid homeostasis in mice. J Hepatol 46: 151-159, 2007.
53. Hamelet J, Maurin N, Fulchiron R, Delabar JM, Janel N. Mice lacking cystathionine β-synthase have lung fibrosis and air space enlargement. Exp Mol Pathol 83: 249-253, 2007.
54. Hamelet J, Noll C, Ripoll C, Paul JL, Janel N, Delabar JM. Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice. Biochem Biophys Res Commun 378: 673-677, 2009.
55. Hamelet J, Seltzer V, Petit E, Noll C, Andreau K, Delabar JM, Janel N. Cystathionine β-synthase deficiency induces catalase-mediated hydrogen peroxide detoxification in mice liver. Biochim Biophys Acta 1782: 482-488, 2008.
56. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127: 212-219, 2004.
57. Herrmann W, Lorenzl S, Obeid R. [Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders- current evidence and preliminary recommendations]. Fortschr Neurol Psychiatr 75: 515-527, 2007.
58. Hisatomi A, Yamamoto K. [Apolipoprotein B(apoB100, apoB48)]. Nippon Rinsho 59, Suppl 2: 109-113, 2001.
59. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107: 675-683, 2001.
60. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 59: 787-793, 2002.
61. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015-2022, 2002.
62. Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun 237: 527-531, 1997.
63. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab 7: 476-484, 2008.
64. Ignoul S, Eggermont J. CBS domains: structure, function, and pathology in human proteins. Am J Physiol Cell Physiol 289: C1369-C1378, 2005.
65. Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, Imano H, Ohira T, Okamura T, Naito Y, Shimamoto T. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 109: 2766-2772, 2004.
66. Jacovina AT, Deora AB, Ling Q, Broekman MJ, Almeida D, Greenberg CB, Marcus AJ, Smith JD, Hajjar KA. Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest 119: 3384-3394, 2009.
67. Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol 59, Suppl 9: 155-167, 2008.
68. Jakubowski H, Boers GH, Strauss KA. Mutations in cystathionine β-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB J 22: 4071-4076, 2008.
69. Jakubowski H, Perla-Kajan J, Finnell RH, Cabrera RM, Wang H, Gupta S, Kruger WD, Kraus JP, Shih DM. Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB J 23: 1721-1727, 2009.
70. Jamaluddin MD, Chen I, Yang F, Jiang X, Jan M, Liu X, Schafer AI, Durante W, Yang X, Wang H. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood 110: 3648-3655, 2007.
71. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298: 1163-1170, 2007.
72. Janosik M, Sokolova J, Janosikova B, Krijt J, Klatovska V, Kozich V. Birth prevalence of homocystinuria in Central Europe: frequency and pathogenicity of mutation c.1105C>T (p R369C) in the cystathionine β-synthase gene. J Pediatr 154: 431-437, 2009.
73. Jiang X, Yang F, Brailoiu E, Jakubowski H, Dun NJ, Schafer AI, Yang X, Durante W, Wang H. Differential regulation of homocysteine transport in vascular endothelial and smooth muscle cells. Arterioscler Thromb Vasc Biol 27: 1976-1983, 2007.
74. Jiang X, Yang F, Tan H, Liao D, Bryan RM Jr, Randhawa JK, Rumbaut RE, Durante W, Schafer AI, Yang X, Wang H. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 25: 2515-2521, 2005.
75. Kabil O, Toaka S, LoBrutto R, Shoemaker R, Banerjee R. Pyridoxal phosphate binding sites are similar in human heme-dependent and yeast heme-independent cystathionine β-synthases. Evidence from 31P NMR and pulsed EPR spectroscopy that heme and PLP cofactors are not proximal in the human enzyme. J Biol Chem 276: 19350-19355, 2001.
76. Kalaria RN. The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev 4: 226-260, 1992.
77. Kamath AF, Chauhan AK, Kisucka J, Dole VS, Loscalzo J, Handy DE, Wagner DD. Elevated levels of homocysteine compromise bloodbrain barrier integrity in mice. Blood 107: 591-593, 2006.
78. Kang AH, Trelstad RL. A collagen defect in homocystinuria. J Clin Invest 52: 2571-2578, 1973.
79. Keebler ME, De Souza C, Fonseca V. Diagnosis and treatment of hyperhomocysteinemia. Curr Atheroscler Rep 3: 54-63, 2001.
80. Kery V, Poneleit L, Kraus JP. Trypsin cleavage of human cystathionine beta-synthase into an evolutionarily conserved active core: structural and functional consequences. Arch Biochem Biophys 355: 222-232, 1998.
81. Khan U, Crossley C, Kalra L, Rudd A, Wolfe CD, Collinson P, Markus HS. Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study. Stroke 39: 2943-2949, 2008.
82. Kimura H. Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. Biochem Biophys Res Commun 267: 129-133, 2000.
83. Kluijtmans LA, Boers GH, Kraus JP, van den Heuvel LP, Cruysberg JR, Trijbels FJ, Blom HJ. The molecular basis of cystathionine β-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet 65: 59-67, 1999.
84. Kluijtmans LA, Boers GH, Trijbels FJ, van Lith-Zanders HM, van den Heuvel LP, Blom HJ. A common 844INS68 insertion variant in the cystathionine β-synthase gene. Biochem Mol Med 62: 23-25, 1997.
85. Knottnerus IL, Govers-Riemslag JW, Hamulyak K, Rouhl RP, Staals J, Spronk HM, van Oerle R, van Raak EP, Lodder J, ten Cate H, van Oostenbrugge RJ. Endothelial activation in lacunar stroke subtypes. Stroke 41: 1617-1622, 2010.
86. Kocer B, Engur S, Ak F, Yilmaz M. Serum vitamin B12, folate, and homocysteine levels and their association with clinical and electrophysiological parameters in multiple sclerosis. J Clin Neurosci 16: 399-403, 2009.
87. 2-dependent manner. Am J Physiol Heart Circ Physiol 292: H1953-H1960, 2007.
88. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr Pharm Des 14: 338-351, 2008.
89. Kraus JP. Molecular analysis of cystathionine β-synthase-a gene on chromosome 21. Prog Clin Biol Res 360: 201-214, 1990.
90. Kraus JP, Janosik M, Kozich V, Mandell R, Shih V, Sperandeo MP, Sebastio G, de Franchis R, Andria G, Kluijtmans LA, Blom H, Boers GH, Gordon RB, Kamoun P, Tsai MY, Kruger WD, Koch HG, Ohura T, Gaustadnes M. Cystathionine β-synthase mutations in homocystinuria. Hum Mutat 13: 362-375, 1999.
91. Kraus JP, Rosenberg LE. Cystathionine β-synthase from human liver: improved purification scheme and additional characterization of the enzyme in crude and pure form. Arch Biochem Biophys 222: 44-52, 1983.
92. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Buttner T, Woitalla D, Muller T. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 40: 225-227, 1998.
93. Kumar M, Tyagi N, Moshal KS, Sen U, Pushpakumar SB, Vacek T, Lominadze D, Tyagi SC. GABAA receptor agonist mitigates homocysteine-induced cerebrovascular remodeling in knockout mice. Brain Res 1221: 147-153, 2008.
94. Kundu S, Kumar M, Sen U, Mishra PK, Tyagi N, Metreveli N, Lominadze D, Rodriguez W, Tyagi SC. Nitrotyrosinylation, remodeling and endothelial-myocyte uncoupling in iNOS, cystathionine β-synthase (CBS) knockouts and iNOS/CBS double knockout mice. J Cell Biochem 106: 119-126, 2009.
95. Latacha KS, Rosenquist TH. Homocysteine inhibits extra-embryonic vascular development in the avian embryo. Dev Dyn 234: 323-331, 2005.
96. Lentz SR. Homocysteine and vascular dysfunction. Life Sci 61: 1205-1215, 1997.
97. Liu F, Zhang J, Yu S, Wang R, Wang B, Lai L, Yin H, Liu G. Effect of folate on neointima formation and matrix metalloproteinase-9 expression after balloon injury in hyperhomocysteinemic rabbits. Int J Cardiol 131: 59-65, 2008.
98. Lominadze D, Roberts AM, Tyagi N, Moshal KS, Tyagi SC. Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol 290: H1206-H1213, 2006.
99. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567-1577, 2006.
100. Looft-Wilson RC, Ashley BS, Billig JE, Wolfert MR, Ambrecht LA, Bearden SE. Chronic diet-induced hyperhomocysteinemia impairs eNOS regulation in mouse mesenteric arteries. Am J Physiol Regul Integr Comp Physiol 295: R59-R66, 2008.
101. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62: 1972-1976, 2004.
102. Maclean KN, Sikora J, Kozich V, Jiang H, Greiner LS, Kraus E, Krijt J, Overdier KH, Collard R, Brodsky GL, Meltesen L, Crnic LS, Allen RH, Stabler SP, Elleder M, Rozen R, Patterson D, Kraus JP. A novel transgenic mouse model of CBS-deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hypercoagulative phenotype that is ameliorated by betaine treatment. Mol Genet Metab 101: 153-162, 2010.
103. Maclean KN, Sikora J, Kozich V, Jiang H, Greiner LS, Kraus E, Krijt J, Overdier KH, Collard R, Brodsky GL, Meltesen L, Crnic LS, Allen RH, Stabler SP, Elleder M, Rozen R, Patterson D, Kraus JP. A novel transgenic mouse model of CBS-deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hypercoagulative phenotype that is ameliorated by betaine treatment. Mol Genet Metab 101: 153-162.
104. Maclullich AM, Ferguson KJ, Reid LM, Deary IJ, Starr JM, Seckl JR, Bastin ME, Wardlaw JM. Higher systolic blood pressure is associated with increased water diffusivity in normal-appearing white matter. Stroke 40: 3869-3871, 2009.
105. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537, 2000.
106. Makins RJ, Gertner DJ, Lee PJ. Acute pancreatitis in homocystinuria. J Inherit Metab Dis 23: 190-191, 2000.
107. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med 60: 39-54, 2009.
108. Martinez-Poveda B, Chavarria T, Sanchez-Jimenez F, Quesada AR, Medina MA. An in vitro evaluation of the effects of homocysteine thiolactone on key steps of angiogenesis and tumor invasion. Biochem Biophys Res Commun 311: 649-653, 2003.
109. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128, 1969.
110. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 33: 2351-2356, 2002.
111. Meng QH, Yang G, Yang W, Jiang B, Wu L, Wang R. Protective effect of hydrogen sulfide on balloon injury-induced neointima hyperplasia in rat carotid arteries. Am J Pathol 170: 1406-1414, 2007.
112. Miles EW, Kraus JP. Cystathionine β-synthase: structure, function, regulation, and location of homocystinuria-causing mutations. J Biol Chem 279: 29871-29874, 2004.
113. Minamishima S, Bougaki M, Sips PY, Yu JD, Minamishima YA, Elrod JW, Lefer DJ, Bloch KD, Ichinose F. Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3-dependent mechanism in mice. Circulation 120: 888-896, 2009.
114. Moat SJ, Bao L, Fowler B, Bonham JR, Walter JH, Kraus JP. The molecular basis of cystathionine β-synthase (CBS) deficiency in UK and US patients with homocystinuria. Hum Mutat 23: 206, 2004.
115. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 37: 1-31, 1985.
116. Munke M, Kraus JP, Ohura T, Francke U. The gene for cystathionine β-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17. Am J Hum Genet 42: 550-559, 1988.
117. 2S signals through protein S-sulfhydration. Sci Signal 2: ra72, 2009.
118. Namekata K, Enokido Y, Ishii I, Nagai Y, Harada T, Kimura H. Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia. J Biol Chem 279: 52961-52969, 2004.
119. Olson KR. Hydrogen sulfide and oxygen sensing in the cardiovascular system. Antioxid Redox Signal 211: 2727-2734, 2008.
120. Olson KR, Whitfield NL, Bearden SE, St Leger J, Nilson E, Gao Y, Madden JA. Hypoxic pulmonary vasodilation: a paradigm shift with a hydrogen sulfide mechanism. Am J Physiol Regul Integr Comp Physiol 298: R51-R60, 2010.
121. - donor NaHS releases nitric oxide from nitrosothiols, metal nitrosyl complex, brain homogenate and murine L1210 leukaemia cells. Pflügers Arch 457: 271-279, 2008.
122. Ovechkin AV, Tyagi N, Sen U, Lominadze D, Steed MM, Moshal KS, Tyagi SC. 3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice. Am J Physiol Lung Cell Mol Physiol 291: L905-L911, 2006.
123. Parrot F, Redonnet-Vernhet I, Lacombe D, Gin H. Osteoporosis in late-diagnosed adult homocystinuric patients. J Inherit Metab Dis 23: 338-340, 2000.
124. Patil RV, Kulthe SG, Boby KF, Karande SC, Jain MK. Chronic pancreatitis in homocystinuria. Indian Pediatr 32: 469-470, 1995.
125. 2 sensing in the carotid body. Proc Natl Acad Sci USA 107: 10719-10724, 2010.
126. Powers RW, Majors AK, Lykins DL, Sims CJ, Lain KY, Roberts JM. Plasma homocysteine and malondialdehyde are correlated in an age-and gender-specific manner. Metabolism 51: 1433-1438, 2002.
127. Predmore BL, Lefer DJ. Development of hydrogen sulfide-based therapeutics for cardiovascular disease. J Cardiovasc Transl Res 3: 487-498, 2010.
128. Price J, Vickers CF, Brooker BK. A case of homocystinuria with noteworthy dermatological features. J Ment Defic Res 12: 111-118, 1968.
129. Pryor WA, Houk KN, Foote CS, Fukuto JM, Ignarro LJ, Squadrito GL, Davies KJ. Free radical biology and medicine: it's a gas, man! Am J Physiol Regul Integr Comp Physiol 291: R491-R511, 2006.
130. Ramsaransing GS, Fokkema MR, Teelken A, Arutjunyan AV, Koch M, De Keyser J. Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry 77: 189-192, 2006.
131. Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 20: 519-529, 1999.
132. Refsum H, Fredriksen A, Meyer K, Ueland PM, Kase BF. Birth prevalence of homocystinuria. J Pediatr 144: 830-832, 2004.
133. Robert K, Maurin N, Ledru A, Delabar J, Janel N. Hyperkeratosis in cystathionine β-synthase-deficient mice: an animal model of hyperhomocysteinemia. Anat Rec A Discov Mol Cell Evol Biol 280: 1072-1076, 2004.
134. Robert K, Maurin N, Vayssettes C, Siauve N, Janel N. Cystathionine β-synthase deficiency affects mouse endochondral ossification. Anat Rec A Discov Mol Cell Evol Biol 282: 1-7, 2005.
135. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 92: 2825-2830, 1995.
136. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpiot P, Bodard H, Ghiringhelli O, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 91: 1161-1174, 1995.
137. Sahin S, Aksungar FB, Topkaya AE, Yildiz Z, Boru UT, Ayalp S, Karsidag S. Increased plasma homocysteine levels in multiple sclerosis. Mult Scler 13: 945-946, 2007.
138. Schimke RN, McKusick VA, Pollack AD. Homocystinuria simulating the Marfan syndrome. Trans Assoc Am Physicians 78: 60-72, 1965.
139. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332: 286-291, 1995.
140. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476-483, 2002. (Pubitemid 34441738)
141. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, Yoshita M, Rosenberg IH, D'Agostino RB, DeCarli C. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 65: 642-649, 2008.
142. Sessa WC. eNOS at a glance. J Cell Sci 117: 2427-2429, 2004.
143. Shastry S, Tyagi N, Hayden MR, Tyagi SC. Proteomic analysis of homocysteine inhibition of microvascular endothelial cell angiogenesis. Cell Mol Biol (Noisy-le-grand) 50: 931-937, 2004.
144. Shentu TP, Titushkin I, Singh DK, Gooch KJ, Subbaiah PV, Cho M, Levitan I. oxLDL-induced decrease in lipid order of membrane domains is inversely correlated with endothelial stiffness and network formation. Am J Physiol Cell Physiol 299: C218-C229, 2010.
145. Singh S, Madzelan P, Banerjee R. Properties of an unusual heme cofactor in PLP-dependent cystathionine beta-synthase. Nat Prod Rep 24: 631-639, 2007.
146. Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, Gottfries CG, Blennow K. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 50: 966-971, 1998.
147. Sperandeo MP, de Franchis R, Andria G, Sebastio G. A 68-bp insertion found in a homocystinuric patient is a common variant and is skipped by alternative splicing of the cystathionine β-synthase mRNA. Am J Hum Genet 59: 1391-1393, 1996.
148. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Off Arch Intern Med 158: 1301-1306, 1998.
149. Symons JD, Zaid UB, Athanassious CN, Mullick AE, Lentz SR, Rutledge JC. Influence of folate on arterial permeability and stiffness in the absence or presence of hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 26: 814-818, 2006.
150. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935, 2007.
151. Tan H, Jiang X, Yang F, Li Z, Liao D, Trial J, Magera MJ, Durante W, Yang X, Wang H. Hyperhomocysteinemia inhibits post-injury reendothelialization in mice. Cardiovasc Res 69: 253-262, 2006.
152. Teunissen CE, Killestein J, Kragt JJ, Polman CH, Dijkstra CD, Blom HJ. Serum homocysteine levels in relation to clinical progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 79: 1349-1353, 2008.
153. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the
154. Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry 81: 192-197, 2010.
155. Troen AM. The central nervous system in animal models of hyperhomocysteinemia. Prog Neuropsychopharmacol Biol Psychiatry 29: 1140-1151, 2005.
156. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 91: 6369-6373, 1994.
157. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet 59: 1262-1267, 1996.
158. Tyagi N, Givvimani S, Qipshidze N, Kundu S, Kapoor S, Vacek JC, Tyagi SC. Hydrogen sulfide mitigates matrix metalloproteinase-9 activity and neurovascular permeability in hyperhomocysteinemic mice. Neurochem Int 56: 301-307, 2010.
159. Ueland PM, Nygard O, Vollset SE, Refsum H. The Hordaland Homocysteine Studies. Lipids Suppl 36: S33-S39, 2001.
160. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10: 463-470, 2003.
161. Undas A, Perla J, Lacinski M, Trzeciak W, Kazmierski R, Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 35: 1299-1304, 2004.
162. van der Griend R, Haas FJ, Duran M, Biesma DH, Meuwissen OJ, Banga JD. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 132: 67-72, 1998.
163. Ventura E, Durant R, Jaussent A, Picot MC, Morena M, Badiou S, Dupuy AM, Jeandel C, Cristol JP. Homocysteine and inflammation as main determinants of oxidative stress in the elderly. Free Radic Biol Med 46: 737-744, 2009.
164. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MM. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 51: 285-289, 2002. (Pubitemid 34206283)
165. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 325: 1202, 2002.
166. Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, Yang X, Berger PB, Durante W, Pownall HJ, Schafer AI. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine β-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 101: 3901-3907, 2003.
167. Wang L, Chen X, Tang B, Hua X, Klein-Szanto A, Kruger WD. Expression of mutant human cystathionine β-synthase rescues neonatal lethality but not homocystinuria in a mouse model. Hum Mol Genet 14: 2201-2208, 2005.
168. Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, Zhu YC. The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. Antioxid Redox Signal 12: 1065-1077, 2010.
169. Wardlaw JM, Doubal F, Armitage P, Chappell F, Carpenter T, Munoz Maniega S, Farrall A, Sudlow C, Dennis M, Dhillon B. Lacunar stroke is associated with diffuse blood-brain barrier dysfunction. Ann Neurol 65: 194-202, 2009.
170. Wardlaw JM, Farrall A, Armitage PA, Carpenter T, Chappell F, Doubal F, Chowdhury D, Cvoro V, Dennis MS. Changes in background blood-brain barrier integrity between lacunar and cortical ischemic stroke subtypes. Stroke 39: 1327-1332, 2008.
171. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 34: 806-812, 2003.
172. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, Maeda N. Mice deficient in cystathionine β-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci USA 92: 1585-1589, 1995.
173. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine β-synthase-deficient mice. Arterioscler Thromb Vasc Biol 22: 34-41, 2002.
174. Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JF Jr, Loscalzo J. Influence of hyperhomocysteinemia on the cellular redox state-impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 41: 1455-1461, 2003.
175. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, Austin RC. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 107: 1263-1273, 2001.
176. Whiteman M, Li L, Kostetski I, Chu SH, Siau JL, Bhatia M, Moore PK. Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. Biochem Biophys Res Commun 343: 303-310, 2006.
177. Wilson KM, McCaw RB, Leo L, Arning E, Lhotak S, Bottiglieri T, Austin RC, Lentz SR. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27: 233-240, 2007.
178. Wisniewski HM, Kozlowski PB. Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT). Ann NY Acad Sci 396: 119-129, 1982.
179. Wong A, Mok V, Fan YH, Lam WW, Liang KS, Wong KS. Hyperhomocysteinemia is associated with volumetric white matter change in patients with small vessel disease. J Neurol 253: 441-447, 2006.
180. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, Sacco RL, DeCarli C. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke 36: 1207-1211, 2005.
181. Yang G, Sun X, Wang R. Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3. FASEB J 18: 1782-1784, 2004.
182. Zhang D, Jiang X, Fang P, Yan Y, Song J, Gupta S, Schafer AI, Durante W, Kruger WD, Yang X, Wang H. Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine β-synthase-deficient mice. Circulation 120: 1893-1902, 2009.
183. Zhou J, Werstuck GH, Lhotak S, Shi YY, Tedesco V, Trigatti B, Dickhout J, Majors AK, DiBello PM, Jacobsen DW, Austin RC. Hyperhomocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6J mice. FASEB J 22: 2569-2578, 2008.
184. Zhuo JM, Pratico D. Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol 45: 195-201.
185. Zieminska E, Stafiej A, Lazarewicz JW. Role of group I metabotropic glutamate receptors and NMDA receptors in homocysteine-evoked acute neurodegeneration of cultured cerebellar granule neurones. Neurochem Int 43: 481-492, 2003.
186. Zoccolella S, Dell'aquila C, Specchio LM, Logroscino G, Lamberti P. Elevated homocysteine levels in Parkinson's disease: is there anything besides L-Dopa treatment? Curr Med Chem; http://www.benthamdirect. org/pages/content. php?cmc/2010/00000017/00000003/0003C.SGM.
187. Zou CG, Banerjee R. Tumor necrosis factor-α-induced targeted proteolysis of cystathionine beta-synthase modulates redox homeostasis. J Biol Chem 278: 16802-16808, 2003.